WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Ouvrir ce répertoire et afficher son contenuParasitic infections
Ouvrir ce répertoire et afficher son contenuInsect and arachnid bites and stings
Ouvrir ce répertoire et afficher son contenuSuperficial fungal infections
Ouvrir ce répertoire et afficher son contenuSubcutaneous fungal infections
Ouvrir ce répertoire et afficher son contenuBacterial infections
Ouvrir ce répertoire et afficher son contenuViral infections
Ouvrir ce répertoire et afficher son contenuEczematous diseases
Ouvrir ce répertoire et afficher son contenuScaling diseases
Ouvrir ce répertoire et afficher son contenuPapulosquamous diseases
Afficher le documentCutaneous reactions to drugs
Ouvrir ce répertoire et afficher son contenuPigmentary disorders
Ouvrir ce répertoire et afficher son contenuPremalignant lesions and malignant tumours
Ouvrir ce répertoire et afficher son contenuPhotodermatoses
Ouvrir ce répertoire et afficher son contenuBullous dermatoses
Afficher le documentAlopecia areata
Afficher le documentUrticaria
Ouvrir ce répertoire et afficher son contenuConditions common in children
Afficher le documentAcne vulgaris
Afficher le documentPruritus
Afficher le documentTropical ulcers
Ouvrir ce répertoire et afficher son contenuAntimicrobial drugs
Fermer ce répertoireAntifugal drugs
Afficher le documentAmphotericin B
Afficher le documentBenzoic acid + salicylic acid (Whitfield’s ointment)
Afficher le documentClotrimazole
Afficher le documentEconazole
Afficher le documentFluconazole
Afficher le documentFlucytosine
Afficher le documentGriseofulvin
Afficher le documentItraconazole
Afficher le documentKetoconazole
Afficher le documentMiconazole
Afficher le documentNystatin
Afficher le documentPotassium iodide
Afficher le documentSelenium sulfide
Afficher le documentSodium thiosulfate
Afficher le documentTerbinafine
Ouvrir ce répertoire et afficher son contenuAntiseptic agents
Ouvrir ce répertoire et afficher son contenuKeratoplastic and keratolytic agents
Ouvrir ce répertoire et afficher son contenuScabicides and pediculicides
Ouvrir ce répertoire et afficher son contenuAnti-inflammatory and antipruritic drugs1
Ouvrir ce répertoire et afficher son contenuAntiallergics and drugs used in anaphylaxis
Ouvrir ce répertoire et afficher son contenuUltraviolet radiation-blocking agents (sunscreens)
Ouvrir ce répertoire et afficher son contenuMiscellaneous drugs
Ouvrir ce répertoire et afficher son contenuAnnex
Afficher le documentSelected WHO Publications of Related Interest
Afficher le documentBack cover
 

Itraconazole

Capsule, 100 mg

General information

Itraconazole is a triazole derivative with a broad spectrum of antifungal activity. It is well absorbed and passes readily across the blood-brain barrier into the cerebrospinal fluid. The plasma half-life is about 30 hours. It is metabolized in the liver and eliminated in the urine.

The drug is currently expensive, which may limit its availability.

Clinical information

Uses

Treatment of:

• oropharyngeal and vulvovaginal candidosis
• resistant dermatophyte infections of the skin
• subcutaneous fungal infections, including sporotrichosis, chromomycosis and zygomycosis
• systemic fungal infections, including histoplasmosis and paracoccidioido-mycosis,1 with skin involvement.

1 For further information, see WHO model prescribing information: drugs used in sexually transmitted diseases and HIV infection. Geneva, World Health Organization, 1995.

Dosage and administration

All doses are suitable for adults and children over 12 years.

Oropharyngeal candidosis:

100 mg daily for 15 days.

Vulvovaginal candidosis:

400 mg in two divided doses taken on the same day.

Resistant dermatophyte infections of the skin:

200 mg daily for 15-30 days.

Higher dosages may be needed in patients with associated infections of the nails: 400 mg daily for 7 consecutive days per month for 3 months.

Subcutaneous and systemic fungal infections:

200-400 mg daily for as long as lesions persist.

Contraindications

• Known hypersensitivity to azole derivatives.
• Severe hepatic impairment.
• Age under 12 years.

Precautions

Dosage should be reduced in accordance with the creatinine clearance rate in patients with renal impairment.

Hepatic function should be monitored when treatment is prolonged.

Women of child-bearing age should take effective contraceptive precautions during treatment and for several weeks thereafter.

Use in pregnancy and lactation

Itraconazole has been shown to have teratogenic potential when given in high doses to experimental animals. The need for treatment must be determined by the condition of the mother. Breast-feeding should be interrupted during treatment.

Adverse effects

Itraconazole is generally well tolerated. Nausea is the most frequently reported adverse effect. Vomiting and abdominal distension and discomfort have also been reported.

Elevation of hepatic enzyme levels, which occurs in a small percentage of individuals, is readily reversible in the early stages. Treatment should be discontinued if signs develop that are suggestive of hepatic disease.

Itraconazole should be withdrawn if skin rashes progress during treatment. Exfoliative skin disorders have been reported, but a causal association has not been established.

Anaphylaxis occurs rarely.

Drug interactions

The hepatic metabolism of other lipid-soluble drugs, including ciclosporin, phenytoin, sulfonylureas, theophylline and warfarin, is inhibited.

Rifampicin accelerates the clearance of itraconazole.

Concomitant administration of terfenadine should be avoided since it has been associated with serious, sometimes fatal, cardiac dysrhythmias.

Overdosage

No experience has been gained with overdosage of itraconazole. Induction of emesis and gastric lavage may be tried in the case of accidental overdosage.

Storage

Capsules should be kept in well-closed containers, protected from light.

vers la section précédente
vers la section suivante
 
 
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 1 décembre 2019